News: International Primary Immunodeficiencies Congress (IPIC2023) - FAIS Africa

February 2, 2023 | |

FAIS is happy to support the International Primary Immunodeficiencies Congress (IPIC2023), taking place in Rotterdam, the Netherlands from November 8-10, 2023.

It will be the occasion to bring back together clinicians with an interest in primary immunodeficiencies (PIDs)/ inborn errors of immunity (IEI) alongside leading physicians in the field, patient organisation representatives, nurses, industry representatives and other interested stakeholders.

IPIC has established itself as one of the leading international congresses on PID clinical care with a unique approach to its scientific programme underpinned by its focus on patient-centredness. With a truly international impact, the congress has earned its definite place and role in the PID clinical landscape. The CME-accredited clinical programme of IPIC is designed to complement other existing PID international congresses and regional scientific meetings.

The IPIC2023 programme will feature international key opinion leaders in the field and seek to engage international delegates in thought-provoking and interactive sessions. Key topics will include, among others:

  • Newborn Screening
  • Management of Neurological manifestations in PIDs
  • Transplantation challenges in PIDs
  • Cancer and immunity
  • Ethical considerations
  • Discussion of complex cases of PIDs
  • Clinical development of PIDs


The deadline for abstract submissions and travel grant applications for IPIC2023 has been extended until June 30, 2023.

Click here for more details on how to submit your abstract.

Additionally, IPOPI is offering 20 travel grants to enable junior doctors to attend IPIC2023 in Rotterdam. We encourage you to apply, and priority will be given to applicants who have submitted an abstract for a poster presentation. The submission deadline is June 30, 2023.

For more detailed information, please refer to the attached informational leaflet or find it online here.

More info here.